Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
25 Apr 2018
Change (% chg)

$0.03 (+1.16%)
Prev Close
$2.58
Open
$2.58
Day's High
$2.62
Day's Low
$2.54
Volume
196,796
Avg. Vol
308,092
52-wk High
$4.24
52-wk Low
$0.57

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $454.30
Shares Outstanding(Mil.): 118.31
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.56 -- --
ROI: -166.61 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Aveo Quarterly Loss Per Share $0.08

* AVEO REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

13 Mar 2018

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

16 Feb 2018

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

12 Feb 2018

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

26 Dec 2017

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

07 Dec 2017

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

30 Nov 2017

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07 Nov 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥3,715 -13.00
Eisai Co., Ltd (4523.T) ¥7,280 -84.00
Pfizer Inc. (PFE.N) $36.68 -0.38
Novartis AG (NOVN.S) CHF75.24 -0.52
Roche Holding Ltd. (ROG.S) CHF217.75 -1.45
Roche Holding Ltd. (RO.S) CHF222.60 -1.20
Bayer AG (BAYGn.DE) €97.47 -0.50
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.87 --
AstraZeneca plc (AZN.L) 4,991.00 +1.50

Earnings vs. Estimates